New drug combo targets tough lung cancer in early trial

NCT ID NCT02496663

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-phase trial studies the safety and best dose of adding necitumumab to osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. About 138 participants will receive the combination to see if it is tolerable and effective. The goal is to find a better way to control the disease when standard options stop working.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC LUNG NON-SMALL CELL CARCINOMA RECURRENT LUNG NON-SMALL CELL CARCINOMA STAGE IV LUNG CANCER AJCC V8

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke Cancer Center Cary

Cary, North Carolina, 27518, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Emory Saint Joseph's Hospital

Atlanta, Georgia, 30342, United States
Emory University Hospital Midtown

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
MedStar Georgetown University Hospital

Washington D.C., District of Columbia, 20007, United States
Stanford Cancer Institute Palo Alto

Palo Alto, California, 94304, United States
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.